2.7 million people worldwide (250,000 Europeans) have kidney transplants or undergo a dialysis treatment because of irreversible end-stage renal disease (ESRD). This number has more than doubled over the past 15 years and involves 3-5% of NHS budgets. The innovative solution provides the safest and efficient automated peritoneal dialysis therapy to date. It entails a comprehensive system composed by a sterile connector (renders peritonitis risk almost zero), a biosensing control system (avoids overfilling), and a new biocompatible dialysate which prevents degradation of peritoneal membrane cells. The cycle is equipped with special biosensors to measure the concentration of glucose and pH, this allows to customize the dialysis prescription according to the ultrafiltration capacity of the patient, increases the safety level of the treatment and it allows to monitor the uptake of glucose by the patient.
